NEW YORK, Jan. 4, 2017 /PRNewswire/ -- Hundreds of Taxotere lawsuits filed over the cancer drug's alleged potential to cause permanent hair loss (alopecia) continue to move forward in the U.S. District Court, Eastern District of Louisiana. According to an Order issued on December 21, 2016, the Court convened a meeting with the parties' Liaison Counsel on December 19th, resulting in the establishment of several new deadlines. Among other things, the Order directs Counsel to draft and submit a proposed Common Benefit Order to the Court by Friday, January 6, 2017. Proposed Plaintiff and Defendant Fact Sheets are to be submitted by January 13, 2017. The Order also directs Counsel to confer regarding the scheduling of a proposed "Science Day/Presentation" with the Court in February. (In Re: Taxotere (Docetaxal) Products Liability Litigation - MDL No. 2740)
"Our Firm is investigating a number of potential cases involving Taxotere and permanent alopecia. We are pleased that the Taxotere litigation is progressing, and look forward to further developments in the year to come," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is now offering free case reviews to breast cancer patients and others who experienced permanent hair loss allegedly associated with Taxotere cancer treatment.
Taxotere Permanent Hair Loss Allegations
Taxotere is a chemotherapy agent marketed by Sanofi-Aventis. Approved in 1996 to treat breast cancer, its approved indications have since been expanded to include head and neck cancer, gastric cancer, prostate cancer and non-small cell lung cancer. Despite being available in the U.S. for two decades, it wasn't until December 2015 that any information regarding reports of permanent alopecia was included on the labeling provided to doctors and patients in this country.
Court documents indicate that more than 260 Taxotere lawsuits have been filed in the federal litigation on behalf of individuals who allegedly experienced permanent hair loss due to treatment with the medication. While alopecia is a common side effect of chemotherapy, plaintiffs claim that Taxotere is more likely to result in the permanent loss of hair compared to alternative, equally effective drugs. They also claim that Sanofi-Aventis has long provided information regarding the potential for permanent alopecia to individual patients and regulatory agencies overseas, even as Taxotere's U.S. label only included a generic, vague, and insufficient warning that "hair generally grows back".
Cancer patients who allegedly experienced permanent hair loss following chemotherapy with Taxotere may be entitled to compensation for their emotional distress and other damages. To learn more about filing a Taxotere lawsuit, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
SOURCE Bernstein Liebhard LLP